Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective

INTRODUCTION: To evaluate the cost-effectiveness of the co-formulation insulin degludec/insulin aspart (IDegAsp) versus biphasic insulin aspart (BIAsp 30), both administered twice daily, in patients with type 2 diabetes mellitus (T2DM), using a short-term cost-effectiveness model. METHODS: Data from...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Marc, Gundgaard, Jens, Hansen, Brian Bekker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118233/
https://www.ncbi.nlm.nih.gov/pubmed/27553066
http://dx.doi.org/10.1007/s13300-016-0195-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118233/
https://www.ncbi.nlm.nih.gov/pubmed/27553066
http://dx.doi.org/10.1007/s13300-016-0195-6

Ejemplares similares